CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 30, 2017--
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical
oncology company advancing novel product candidates based on its
Targeted Protein Therapeutics (TPTs) platform, today announced that
Stephen Hurly, President and Chief Executive Officer, will present a
company overview at the LD Micro Main Event 2017 in Los Angeles, CA on
Thursday, December 7, 2017 at 8:30 a.m. PST.
A live webcast can be accessed from the Investors & Media section of
Eleven's website, www.elevenbio.com.
An archived replay of the webcast will be available on the Company's
website for 90 days after the conference.
About Eleven Biotherapeutics
Eleven Biotherapeutics, Inc. is a late-stage, clinical oncology company
advancing novel product candidates based upon the Company’s targeted
protein therapeutics (TPTs) platform. TPTs incorporate a tumor-targeting
antibody fragment and a protein cytotoxic payload into a single protein
molecule in order to achieve focused tumor cell killing. Eleven’s lead
TPT, Vicinium, is currently in a Phase 3 trial in non-muscle invasive
bladder cancer, with topline three-month data expected in mid-2018. The
Company believes its TPT approach offers significant advantages in
treating cancer over existing antibody drug conjugate technologies. The
Company believes its TPTs provide effective tumor targeting with broader
cancer cell-killing properties than are achievable with small molecule
payloads that require tumor cell proliferation and face multi-drug
resistant mechanisms. Additionally, the Company believes that its TPT’s
cancer cell-killing properties promote an anti-tumor immune response
that will potentially combine well with immune oncology drugs such as
checkpoint inhibitors. For more information, please refer to the
Company’s website at www.elevenbio.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171130006163/en/
Source: Eleven Biotherapeutics, Inc.
Stern Investor Relations, Inc.
Michael Schaffzin, 212-362-1200